Early inhibition of IL-6 signalling after an acute MI improves myocardial salvage

A new randomized clinical trial shows that tocilizumab, a monoclonal antibody that inhibits IL-6 signalling by binding to the IL-6 receptor, increases myocardial salvage in patients with acute ST-segment elevation myocardial infarction who undergo myocardial revascularization with percutaneous coronary intervention.